Engineered pathways for correct disulfide bond oxidation

Guoping Ren and James C. A. Bardwell

Howard Hughes Medical Institute, Department of Molecular, Cellular and Developmental Biology, University of Michigan, Ann Arbor, MI 48109

To whom correspondence should be addressed:

James C. A. Bardwell
830 N. University Ave.
University of Michigan
Ann Arbor, Mi 48109-1048
Tel.: 734-764-8028; Fax: 734-764-0884
Email: jbardwel@umich.edu

Manuscript Type: Original Research Communication

Running title: Engineered pathways for correct disulfide formation

Text word count: 6010

Reference number: 45
Abstract

Correct formation of disulfide bonds is critical for protein folding. We find that cells lacking protein disulfide isomerases can use alternative mechanisms for correct disulfide bond formation. By linking correct disulfide bond formation to antibiotic resistance, we selected mutants that catalyze correct disulfide formation in the absence of DsbC, *Escherichia coli*'s principle disulfide isomerase. Most of our mutants massively overproduce the disulfide oxidase DsbA and change its redox status. They enhance DsbA’s ability to directly form the correct disulfides by increasing the level of mixed disulfides between DsbA and substrate proteins. One mutant operates via a different mechanism; it contains mutations in DsbB and CpxR that alter the redox environment of the periplasm and increases the level of the chaperone/protease DegP, allowing DsbA to gain disulfide isomerase ability in vivo. Thus, given the proper expression level, redox status, and chaperone assistance, the oxidase DsbA can readily function in vivo to catalyze the folding of proteins with complex disulfide bond connectivities. Our selection reveals versatile strategies for correct disulfide formation in vivo. Remarkably, our evolution of new pathways for correct disulfide bond formation in *E. coli*, mimics eukaryotic protein disulfide isomerase, a highly abundant partially reduced protein with chaperone activity.
Introduction

Disulfide bonds act to stabilize many protein structures (8). The stability of disulfide-rich miniproteins, for instance, is almost entirely dependent upon disulfide bonds (9). Although disulfide bonds are important for folding and stability, their accurate formation is difficult to achieve. This is particularly true for proteins with high levels of disulfide connectivity, because the number of possible incorrect disulfides grows factorially as the number of cysteine residues increases. In the eukaryotic endoplasmic reticulum, protein disulfide isomerase (PDI), a thioredoxin fold protein, is thought to be a key player in establishing both the initial oxidation state of protein thiols and in establishing proper connectivity (20). PDI may be aided in these tasks by other thioredoxin-related proteins present in the endoplasmic reticulum and by the reduced glutathione (GSH)/oxidized glutathione (GSSG) redox buffer (16, 20). Thus, in eukaryotic organisms, the pathways responsible for the initial oxidation of disulfides and their proofreading or isomerization are thought to be substantially intermingled.

In contrast, in the bacteria *Escherichia coli*, it has long been thought that the disulfide oxidation and disulfide error correction systems are separate entities (14, 41). DsbA efficiently oxidizes substrates co-translocationally by forming disulfides between cysteines that are adjacent in the amino acid sequence (consecutive disulfides) (6, 25). DsbA is then reoxidized by the membrane bound protein DsbB (4-5). DsbA has very little proofreading or disulfide isomerase activity (43). Proteins with nonconsecutive disulfides are thought to require the action of the *E. coli* disulfide isomerase, DsbC, to correct mistaken disulfide linkages formed by DsbA (14). In order to attack incorrect disulfides, DsbC must be kept in a reduced form. This function is performed by the membrane protein DsbD, which in turn is kept reduced by
the cytosolic thioredoxin, a thioredoxin-reductase and NADPH-dependent system (26,28). DsbC may correct errors in disulfide formation via two principle mechanisms, a reductive mechanism and a direct isomerase mechanism (18,37). Both mechanisms share a key step in which the reduced isomerase attacks incorrect disulfides, resulting in the formation of a mixed disulfide between the isomerase and the substrate protein. Although it has previously been suggested that DsbG, a protein related to DsbC, may assist in the isomerization of disulfide bonds as well, DsbG has almost no isomerization activity in vitro (22). Instead, it now appears that DsbG is involved in detoxifying sulfenic acid formation (13). Thus, DsbC appears to be the predominant disulfide isomerase present in *E. coli*, although it has been reported that DsbA has significant isomerase activity in vivo in that it is able to correctly express RNaseI a protein that contains one nonconsecutive disulfide bond(30)

To generate a selection system that allows us to directly link correct disulfide bond formation to bacterial resistance, we engineered an additional nonconsecutive disulfide into the ampicillin-resistance protein β-lactamase. This strategy opened up the possibility of selecting for *E. coli* variants that could catalyze disulfide bond isomerization in the absence of DsbC. The selected mutants were capable of efficiently expressing a variety of proteins with multiple disulfide containing proteins in an *E. coli* strain that lacks DsbC. All but one of these *dsbC* bypass mutants act by massively overproducing DsbA, which apparently increases the level of mixed disulfides formed between DsbA and substrate proteins. Higher levels of mixed disulfides may in turn allow cells to directly perform correct oxidation of multi-disulfide containing substrates. The remaining *dsbC* bypass mutant that we identified contains mutations in both *dsbB* and *cpxR*, which act to alter the periplasmic chaperone and redox environment and thus favor disulfide isomerization. These results show that by direct selection, we can
easily direct the evolution of multiple alternative mechanisms for correct disulfide formation in vivo.

Materials and Methods

Strains and Growth Conditions. Strains and plasmids used in the study are listed in Table 1. Unless otherwise noted, cultures were grown at 37 °C in LB medium supplemented with appropriate antibiotics. The knockout strains were generated through P1 transduction from the Keio collection stock. A dsbB1-148 truncation was generated by cam cassette insertion immediately after position G148 using the Wanner method(12) in RGP209. Then the cam cassette was removed by pCP20 plasmid to obtain strain RGP1079. RGP1126 was generated by moving the cpxR56 allele from UVC56 to RGP1079 by P1 transduction using kdgT::kan as a selection marker from the Keio collection of knockouts(3). Thus, RGP1126 is the reconstituted strain containing the two only essential mutations from UVC56. The kan cassette was then removed by pCP20 plasmid to obtain strain RGP1146.

Plasmid Construction and Site-Directed Mutagenesis. Point mutations were introduced into the wild type bla gene in pBR322 using a Stratagene Quick Change kit (Stratagene, La Jolla, CA) and appropriate mutagenic primers, and PCR was performed as directed. The product was digested with Dpn I, precipitated using Pelletpaint® according to the protocol supplied by the manufacturer (Novagen) (Dpn I), and resuspended in ~10 µL ddH2O. 5 µL of product was transformed into TG1 competent cells (Stratagene). DNA was extracted from the cells and all point mutations were verified by DNA sequencing. Single disulfide bond β-lactamase mutants were made using a similar strategy but with multiple rounds of the procedure. Overexpression of DsbA was achieved by inserting the dsbA gene into pBAD33 with restriction sites XbaI, and
HindIII. The MBP-BPTI fusion protein was constructed by inserting a codon optimized BPTI after the MBP protein in the pMal-p2 (NEB) vector with the restriction sites SalI and HindIII. Then the TEV protease recognition site of ENLYFQS was immediately inserted before the BPTI sequence.

Mutagenesis, Screening, and Mapping of Mutants Suppressing the \textit{dsbC} Ampicillin Phenotype. RGP209 harboring pBR322 plasmid (R209 hereafter) was mutagenized with UV light. UV irradiated cells were plated to nonselection (Tet) or selection (with 1.5 g/L ampicillin) plates and grown overnight at 37 °C. Colonies appearing on the selection plates were screened on LB plates with 50 µM cadmium to remove the loss-of-function mutants (broken disulfide bond formation machinery also suppresses the \textit{dsbC} null strain phenotype as indicated in Fig. 1C). Colonies surviving the cadmium screen were restreaked to LB plates containing 1.5 g/L ampicillin and subsequently to Tet plates.Suppressor candidates were then collected for further tests to rule out other false-positive possibilities. Plasmids from the colonies were extracted and sequenced to guarantee no mutation in the \textit{bla} gene. PCR validation of the \textit{dsbC} deletion in the genome was done to confirm no environmental bacterial contamination. Linkage of the mutations to the \textit{dsbA} loci was tested by P1 transduction using a \textit{yihG::Kan} strain from the Keio collection. To move the \textit{dsbA} loci region of UVC49, the \textit{yigZ::Kan} strain from the Keio collection was used as selection for P1 transduction. The \textit{dsbA} gene of each mutant was amplified with two primers 100 bp upstream or downstream of \textit{dsbA} and subjected to sequence analysis. For suppressor strain UVC56, \textit{dsbB}, \textit{dsbD} gene were also amplified with primers 100 bp upstream and downstream, respectively, and subjected to sequence analysis. To map the other mutations in the genome, we carried out genome sequencing using a Illumina ("Solexa") Genome Analyzer II. The genomic library was prepared according to Dr. Dave Lazinski, Tufts.
University. Of the 298 sequences tested, differences were observed between ER1821 and UVC56. Five candidate genes (yhjA, dsbB, dsbG, pqiA, and cpxR) were further examined because they mapped to genes that link to envelope proteins potentially involved in protein folding. We checked these candidate genes by P1 transduction of both the wild type genes and the knockout of these genes into UVC56.

**Spot Titers for Ampicillin Resistance, Cadmium Resistance, and Copper Resistance.**

Spot titers for ampicillin resistance were performed to test the β-lactamase or PDI detector β-lactamase activity in vivo. Cadmium resistance was performed to quantify the relative disulfide oxidase activity of the strains in vivo. Spot titers for copper resistance were performed to quantify the relative isomerase or reductase activity in vivo as described. Briefly, strains were grown overnight in LB and diluted 1:100 into fresh LB media with appropriate antibiotics. Strains were grown to mid-logarithmic phase at 37 °C and serially diluted into 150 mM NaCl. A 2 µl aliquote of each dilution was plated onto LB plates with an ampicillin or cadmium gradient, or were plated onto Terrific Broth plates with 15–17 mM CuCl₂. Cells were grown at 37 °C overnight. All spot titers were performed at least in triplicate.

**Urokinase and BPTI Activity Assays.** Urokinase assays were performed on strains transformed with plasmid pRDB8-A, which expresses mouse urokinase plasminogen activator constitutively as described in Reitsch et al(33). Periplasmic extract of bacteria grown to exponential phase were separated on nonreducing SDS-PAGE gels, and urokinase activity was demonstrated by assaying plasminogen activation by using plasminogen-casein agar. Analysis of BPTI activity was done by testing residual trypsin activity (according to the manufacturer Sigma-Aldrich instructions). A 50 µl periplasmic extract was used for a trypsin inhibition assay in a 1 ml reaction using N-α-Benzoyl-L-arginine-4-nitranilide (Roche) as the substrate. 0.5 µg
commercial BPTI was used as a positive control, and a periplasmic extract of cells expressing an empty vector was used as a negative control.

**Motility Assay.** M9 media supplemented with 0.4% (v/v) glycerol as carbon source and free amino acids (40 mg/L each) except cysteine was used to prepare 0.15% (w/v) minimal media motility agar plates. Plates containing cystine and GSSG were also made by supplementing the above with 0.83 mM cystine and 0.83 mM GSSG, respectively. A single colony of the starting strain was inoculated in the middle of the plates and inoculations of the various other strains were placed around the perimeter. After incubation at 37 °C for ~12 h, the diameters of the various strains were visualized.

**4-Acetoamido-4′-maleimidylstilbene2,2′-disulfonic acid (AMS) Trapping.** Strains were grown to mid-logarithmic phase at 37 °C. Cells equivalent to 0.5 OD units were acid-precipitated overnight. Acid-precipitated proteins were solubilized in buffered SDS solution containing 10 mg/ml AMS. The samples were incubated at 30 °C for 30 min, and 37 °C for another 10 min. Alkylation was stopped by the addition of reducing SDS loading buffer and analyzed by electrophoresis and Western blotting.
Results

Linking the Correct Formation of Disulfide Bonds to Bacterial Antibiotic Resistance. In order to ascertain whether there are alternative mechanisms for disulfide isomerization, we decided to select for mutants that can bypass the requirement for the *E. coli* principle isomerase, DsbC. TEM1 β-lactamase is a periplasmic protein that has only a single and therefore consecutive disulfide bond (C52-C98). Although this disulfide increases the folding stability of β-lactamase by 3.5 kJ/mol, it is not essential for ampicillin resistance (17). To make β-lactamase into a probe suitable for the detection of isomerase activity *in vivo* (a “PDI detector”), we designed an additional disulfide bond into the protein by substituting both serine 81 and threonine 108 with cysteine residues; these positions were chosen so that the connectivity of the engineered disulfide would span the native disulfide present in the protein’s primary structure and, if formed correctly, would not substantially disrupt the protein tertiary structure (Fig. 1A and B). Serine 81 and threonine 108 were chosen because they are already very close together in the tertiary structure of β-lactamase. We reasoned that these mutations should convert β-lactamase into an active protein with two nonconsecutive disulfides when oxidized to its native-like conformation (Fig. 1B, iii). Because β-lactamase is secreted into the periplasm linearly (25), we would expect DsbA to initially oxidize the cysteines that are consecutive in the sequence (Fig. 1B, ii), resulting in an incorrect disulfide bonding pattern that very significantly distorts the structure, and thus decrease the activity and antibiotic resistance. Consistent with these considerations, we found that strains containing the β-lactamase PDI detector construct are only highly resistant to ampicillin when DsbC and other components of the DsbC-DsbD disulfide isomerization pathway are present (Fig. 1C and Fig. 2E,F). In the
absence of DsbC or DsbD, the β-lactamase PDI detector is almost fully oxidized (Fig. 1D) but its oxidation pattern appears to be incorrect, as these strains are sensitive to ampicillin. Addition of the small molecule dithiol DTT to the media restores the ampicillin resistance of strains containing the PDI detector construct (Fig. 1E). AMS trapping experiments shown in the insert to Figure 1E indicate that the PDI detector construct is fully oxidized in the presence of DTT implying that DTT is acting as a thiol disulfide exchange reagent that facilitates isomerization rather than a direct reductant. Our results suggest that improper oxidation of β-lactamase is inhibiting its ability to confer resistance. This was substantiated by the observation that in dsbA− strains the PDI detector β-lactamase protein is almost fully reduced and the strains are ampicillin resistant (Fig. 1C), again consistent with the nonessential nature of the native disulfide in β-lactamase. Variants of the β-lactamase PDI detector construct with just a single pair of cysteines that are likely to form nonnative disulfides are sensitive to ampicillin but become resistant to ampicillin in the presence of DTT, providing further evidence that the formation of nonnative disulfides in β-lactamase interferes with its ability to encode ampicillin resistance (Fig. 2A-D). Our disulfide insertion design was based on the β-lactamase crystal structure that predicted that addition of the C81-C108 disulfide would not massively disrupt the β-lactamase structure. In contrast, all other disulfides, apart from the native C52-C98 bond, were expected to disrupt the structure and lead to large decreases in ampicillin resistance. The results shown in Fig. 2 confirm these predictions: the wild type protein containing the C52-C98 disulfide is the most ampicillin resistant, the variant containing the C81-C108 disulfide is somewhat resistant, and all others show lower levels of resistance. We note that the single disulfide bond variant of C81-C108 is not as active as either fully reduced or fully oxidized wild type β-lactamase or fully oxidized PDI detector, as judged by
ampicillin resistance. There are a number of possible explanations for this result: 1) The engineered disulfide C81—C108 may be suboptimal in geometry, resulting in a somewhat stained configuration that in the absence of the original native disulfide bond results in less enzymatic activity than either fully reduced or fully (correctly) oxidized β-lactamase. 2) The cysteine52-serine and cysteine98-serine substitutions may not be entirely neutral, and may decrease the activity of the reduced form of variants containing this mutation. Evidence consistent with this possibility is the previous observation, made by Huang et al (23) in their systematic study of active β-lactamase mutants, that cysteine52 and cysteine98 could be only be substituted with only a very limited number of residues and still allow the β-lactamase protein to retain its ability to encode ampicillin resistance. Significantly cysteine98 could only be substituted with alanine, methionine, leucine and isoleucine but not serine (23). Control experiments showed that the ampicillin resistance of wild type β-lactamase is almost completely unaffected by DsbA, DsbC, or DsbD mutations (Fig. 2F), or by the presence or absence of DTT (Fig. 2B). Taken together, these data suggest that S81C T108C β-lactamase serves as a biomarker to monitor the disulfide isomerase activity present in a strain; henceforth, this construct is simply referred to as the PDI detector.

**dsbC**− **Suppressors Restore Correct Disulfide Bond Formation.** The ampicillin sensitive phenotype of **dsbC**− strains containing the PDI detector provides a powerful and convenient selection for host mutants that allow correct disulfide bond formation. We postulated that host mutations that bypass the need for the disulfide isomerase DsbC would allow strains containing the PDI detector to grow on ampicillin. Because reduced β-lactamase is active, strains that show strongly diminished rates of disulfide bond formation, due for instance to mutations in **dsbA** or **dsbB**, should also result in ampicillin resistance. Strains containing the PDI detector
construct were subjected to five independent rounds of UV mutagenesis, and colonies resistant to 1.5 g/L ampicillin were selected as diagramed in Fig 3. Mutations in \textit{dsbA} or \textit{dsbB} result in sensitivity to the heavy metal cadmium (39). A large number of the mutants that we obtained were cadmium sensitive, indicating that they were either \textit{dsbA}^- or \textit{dsbB}^-; these mutants were not analyzed further. However, 17 mutants resistant to 1.5 g/L ampicillin (4 are shown in Fig. 4A) were cadmium resistant and motile, indicating that they retained oxidase activity. These strains were named UVC49–54 and UVC56–66.

To test if these UVC mutants were enhancing ampicillin resistance through alterations in their ability to form disulfides and not via some disulfide irrelevant mechanism, such as by changing cell permeability to the antibiotic, we examined the periplasmic expression of two other multiple disulfide bond containing proteins whose folding had previously been shown to be DsbC dependent (urokinase and bovine pancreatic trypsin inhibitor [BPTI]) (33) in three of the selected DsbC suppressors (UVC49, UVC52, and UVC56). We found that the activity of the multi-disulfide proteins in these DsbC suppressors was restored to levels at or near those seen in \textit{dsbC}^+ strains (Fig. 4B and Fig. 5C). These results indicated that three different DsbC substrates are at least partially properly oxidized in these DsbC suppressor strains.

In screening these mutants for the presence of DsbA protein via Western analysis, we were struck by the fact that all the strains showed DsbA expression levels that were higher than those seen in wild type backgrounds, with most of the DsbC suppressors exhibiting very high levels of expression (Fig. 4C). DsbA levels were ~50-fold higher in most of the suppressors (UVC49–54, and UVC57–66, Fig. 5A); these were termed class I DsbC suppressors. UVC56 showed only ~5-fold higher DsbA levels and was termed a class II DsbC suppressor (Fig. 5A). Moving the wild type DsbA locus into all 16 of the class I DsbC suppressors by P1 phage co-
transduction resulted in restoration of the loss of ampicillin resistance (Table 2), showing that DsbC suppression activity for these mutants is genetically tightly linked to DsbA overexpression and is caused by a genetic alteration near the DsbA locus. In all cases the protein coding sequence of the DsbA gene was wild type. In contrast, introduction of the wild type DsbA locus into UVC56, the single class II DsbC suppressor, did not decrease its ampicillin resistance, demonstrating that the DsbC suppressor mutation in this strain is unlinked to the DsbA locus (Table 2). In addition, DsbA overexpression off a plasmid in the class I DsbC suppressor UVC52 was sufficient to restore urokinase activity of a dsbC null mutant to wild type levels (Fig. 5D).

The Mechanism of Class I dsbC- Suppression by DsbA Overproduction. We examined the mechanism of action of the DsbC suppressors by conducting thiol trapping experiments. In these experiments, the thiol reactive reagent 4-acetamido-4′-maleimidylstilbene-2,2′-disulfonic acid (AMS) was used to freeze thiol disulfide exchange (19). DsbA crossreactive material was then detected by Western blotting. This approach enabled us to determine the steady-state levels of oxidized and reduced DsbA present in vivo and to detect any mixed disulfides between DsbA and substrate proteins (Fig. 4D). Strikingly, the class I suppressors UVC49 and UVC52 show a massive accumulation (on a per cell basis) of high molecular weight material that crossreacts with the DsbA antibody (Fig. 4D, upper left panel). Because these bands are absent in the presence of DTT, they almost certainly represent disulfide linked DsbA-substrate complexes (25,27). We also observed an increase in the percentage of reduced DsbA present (from ~20% in wild type strains to ~50% in both the class I and II suppressors) (Fig. 4D, lower right panel). As we describe in the Discussion, the increased amounts of both reduced DsbA
and disulfide-linked DsbA-substrate complexes in the Class I suppressors may be important for the ability of these suppressors to catalyze correct disulfide bond formation.

**DsbC Suppression in the Class II Suppressor, UVC56, Requires Mutations in Both dsbB and cpxR.** The second class of DsbC suppressor mutant is represented by a single example, UVC56. Unlike the class I suppressors, UVC56 does not accumulate mixed disulfides with substrates and is resistant to copper (Fig. 5E and Fig. 6D), implying that UVC56 is more proficient in disulfide isomerization than are the class I suppressors. In order to determine which mutations are present in the UVC56 strain, its genome was sequenced and compared with that of the starting strain. There were 298 differences found, but mutations in just two genes, a double mutation in cpxR56 (M23I E24K) and an IS10 insertion mutation in dsbB at G135, accounted for nearly all of the suppression phenotypes. We showed this by constructing a strain (RGP1146) in which the cpxR56 and dsbB::IS10 mutations had been moved into the dsbC null strain RGP209; we found that this strain very closely resembled UVC56 in its high levels of ampicillin, cadmium, and copper resistance (Fig. 6A and D and Fig. 7B). DsbB is the enzyme required for reoxidation of DsbA, and CpxR is a positive regulator of the Cpx periplasmic stress response(10,15). The Cpx regulon is a two component signal transduction pathway that mediates adaptation to periplasmic protein misfolding, that consists of a sensor histidine kinase (CpxA) and a cytoplasmic response regulator (CpxR). DsbA is one of the genes under cpx control (31). We found that reversion of the cpxR M23I E24K mutation decreased the level of DsbA present to wild type levels, showing that the increase in DsbA expression observed for UVC56 was due to this cpxR mutation and implying that this mutation is constitutively active (Fig. 6B). Null mutants of dsbB in which the entire dsbB locus was replaced with a kanamycin resistance cassette gave the same level of suppression of ampicillin
resistance of the PDI detector and the same cadmium resistance as the DsbB truncation, showing that this truncation is exerting its effect as a loss of function mutation. That a strain containing what was effectively a DsbB null mutation could oxidize proteins, as judged by its cadmium resistance, was initially surprising, given that DsbB reoxidizes DsbA and is thus normally very important for disulfide bond formation (5). However, the activity of DsbB can be replaced by adding small disulfide-containing molecules such as cystine and GSSG to the media (5). We found the presence of cystine or GSSG in minimal media was essential for the oxidase activity of UVC56 (Fig. 7A). That these molecules are ineffective in oxidizing DsbA in wild type strains appears to be just a function of DsbA expression level because increasing the level of DsbA 5-fold by plasmid-mediated expression is sufficient to confer cadmium resistance upon a dsbB− dsbC− strain (Fig. 7C). Examination of DsbA’s oxidation status by AMS trapping experiments revealed that more reduced DsbA is present in UVC56 than in wild type strains, both in absolute amount and in the ratio of reduced to oxidized DsbA (Fig. 6B). When the DsbB mutation was replaced by wild type DsbB, the ratio shifted slightly in the oxidized direction. Only when both the dsbB and cpxR genes were wild type was most of the DsbA present in the oxidized form. This result and the fact that DsbA was mostly reduced when only the cpxR gene was made wild type suggests that cpxR also plays a role in determining the redox status of DsbA. CpxR-mediated overproduction of DsbA may make it possible for small molecule disulfides to oxidize DsbA, resulting in a significant portion of DsbA in the oxidized form, though the main fraction remains in the reduced form. Reversion of the dsbB truncation mutation by moving a wild type dsbB locus into UVC56 resulted in a substantial decrease in ampicillin resistance of UVC56 (compare green and blue traces in Fig. 6A). Reversion of both the cpxR and dsbB mutations caused the UVR56 strain to be almost as
ampicillin sensitive as the starting $dsbC^-$ strain (compare yellow and red traces in Fig. 6A). A model that incorporates an important role of both the $cpxR$ and $dsbB$ mutations in the mechanism for class II DsbC suppressors is described in the Discussion.

**Discussion**

**Mechanism of the Class I DsbC suppressors**

Various pathways for the oxidation of substrate proteins by DsbA are shown in Fig 4E. The DsbA-substrate intermediates are shown between steps 1 and 2a, and between steps 2b and 3. Let us first consider the simpler upper reaction pathway consisting of reactions 1 and 2a. In wild type *E. coli*, DsbA is maintained mostly in the oxidized form ($\sim>$80%) by the powerful oxidase DsbB, this and DsbA’s extremely oxidizing redox potential, drives reactions 1 and 2a to completion. The net effect is that DsbA normally very rapidly oxidizes secreted proteins cotranslationally as they emerge into the periplasm, favoring the oxidation of consecutive cysteine pairs. In our DsbC suppressors the amount of proteins secreted into the periplasm likely remains constant, however the amount of DsbA clearly increases. A $\sim$32-fold higher than normal concentration of oxidized DsbA, is present in the periplasm of our Class I DsbC suppressors. This was calculated by multiplying the fold overproduction (50) by the fraction oxidized in the suppressor (0.5) by the fraction oxidized in wild type (0.8) i.e $50 \times 0.5/0.8$.

Given the higher concentration and the strongly oxidizing redox potential of DsbA, it is likely that reaction 1 will be driven forward. The $\sim$125-fold higher concentration of reduced DsbA present in the periplasm of the suppressors ($50 \times 0.5/0.2$) will tend to increase the rate of the back reaction of step 2a. The percentages of oxidized and reduced DsbA and their absolute amounts as determined by AMS trapping are only approximate, so these calculations are not precise. However they serve to illustrate the trends. These two effects should tend to increase
the concentration of mixed disulfide intermediates, as we observed (Fig. 4D upper panels). Increasing the percentage of substrate proteins that are in the form of mixed disulfides with DsbA increases the opportunities for proteins within this population to fold properly, bringing the correct cysteines into close juxtaposition. Dissociation of DsbA from this complex will have the effect of locking in the correct conformation. Because DsbA is a very strong oxidant, reduced DsbA will usually only be effective in reducing incorrect disulfide pairings, which are typically exposed and have relatively high redox potentials. Reduced DsbA will be much less capable of attacking structural disulfides in properly folded proteins, which are typically buried and reducing in redox potential. Thus, once the correct disulfides are formed it will be unlikely that incorrect disulfides will reform.

Another, not mutually exclusive possibility is that the higher level of DsbA leads to a higher level of substrate proteins that, at least transiently, are crosslinked to two or more DsbA molecules via mixed disulfides. The first cysteine on a substrate protein that emerges into the periplasm reacts with DsbA, resulting in the formation of a mixed disulfide (Fig. 4E, step 1). When normal levels of DsbA are present, in the second step (Fig. 4E, step 2a), the second cysteine on the substrate protein to emerge attacks this mixed disulfide. This results in the release of a reduced DsbA molecule and a substrate in which the first two cysteines are joined in a disulfide. Measurements of the rates of these two types of reactions (Fig. 4E, step 1 and step 2a) with glutathione and model peptides show that both reactions occur very rapidly (11). A consequence of these rapid rates is that DsbA will very rapidly react with cysteines on secreted proteins as they emerge into the periplasm (25). The rapid rate of resolution of the mixed disulfide dictates that DsbA will remain in a mixed disulfide with the substrate protein only until an additional cysteine becomes available to resolve the mixed disulfide. Because the
periplasm is a very strongly oxidizing environment, free thiols are generally in short supply; the most available source of a nearby free thiol is very likely the next cysteine on the substrate protein that emerges into the periplasmic space. Thus, DsbA tends to be very effective in crosslinking adjacent thiols on proteins, but much less effective in forming nonconsecutive disulfides (6). However, as the concentration of DsbA within the periplasm increases, it will compete more effectively with cysteines that are consecutive in the substrate protein, and instead, mixed disulfides will be formed. As the protein is synthesized, proper folding can occur and the mixed disulfides will be resolved as correct disulfides are formed in a process such as shown in step 3 of Fig. 4E. Both of these postulated mechanisms will give the substrate protein better opportunities to fold into its proper conformation, bringing the proper cysteines into proximity and allowing for correct disulfide bond formation.

Copper, a redox active metal, is thought to randomly oxidize unpaired cysteines very rapidly, so that in the presence of copper, it is important to have effective thiol/disulfide isomerases (21). Because DsbC corrects the misoxidized disulfides it confers copper resistance to bacteria (Fig. 6D). Curiously, the dsbC suppressor strains, with the exception of UVC56, are not any more resistant to copper than the starting dsbC− strain (Fig. 5E). This further suggests the possibility that instead of being more proficient in disulfide isomerization as we had initially predicted, the majority of the dsbC suppressor strains may actually be better at forming the correct disulfides initially, as would be predicted by the reactions shown in Fig. 4E. This “do once, do it right” strategy would result in higher levels of urokinase, BPTI, and PDI detector expression but not necessarily increase copper resistance.

**Mechanism of Class II DsbC suppressors:**
We considered a model whereby CpxR-mediated overexpression of DsbA, in conjunction with a shift in the ratio of oxidized towards reduced DsbA due to the DsbB truncation, might be sufficient to allow DsbA to effectively function as both an oxidant and as an isomerase in the Class II DsbC suppressors. The UVC56 strain is more resistant to copper than is wild type *E. coli*, and copper resistance is very closely tied to disulfide isomerization (21). We therefore decided to closely investigate the copper resistant phenotype of UVC56. DsbA is absolutely necessary for the copper resistant suppression phenotype (Fig. 6D). Transducing the *cpxR56* point mutation into a DsbC null mutation generated a strain that is as copper resistant as UVC56, showing that *cpxR56* is also very important for the copper resistant phenotype. Thus, both the *dsbA* and *cpxR* loci are strongly implicated in disulfide isomerization. Our results suggest that maintaining DsbA at the appropriate levels and redox status is important for DsbC suppression in our class II suppressors. However, it is unlikely that simply maintaining DsbA at a proper level and redox status is sufficient for isomerase activity because the class I suppressors showed similar ratios of oxidized to reduced DsbA without gaining copper resistance, and DsbA overexpression from a plasmid is not able to rescue copper resistance (Fig. 7C). In UVC56, the DsbA expression level is not regulated by mutations close to the *dsbA* locus but by a mutation in *cpxR*, implicating CpxR regulated genes in the isomerase activity. We found through a genetic screen that *dsbA* and *degP* are both necessary for copper resistance (Fig. 6D). A knockout of DsbA abolished copper resistance, indicating the central role of DsbA in the isomerase activity, and a knockout of DegP strongly decreased copper resistance. A Western blot also showed increased expression of DegP in the UVC56 suppressor strain (Fig. 6C). DegP has been reported to be a protease as well as a chaperone (24,29,34,38). Our result suggests that DegP can play a role in disulfide isomerization as well. The chaperone
activity of DegP may allow it to assist DsbA in disulfide isomerization. Alternatively, the protease activity of DegP might allow it to degrade mis-oxidized substrates that accumulate to levels exceeding Dsb’s isomerization capacity.

Conclusions

The error-correcting disulfide isomerase activity of DsbC allows it to rearrange the disulfides in those few secreted proteins that require nonconsecutive disulfides (Fig. 8). However, the relatively weak isomerase activity of DsbC may be inadequate to accurately oxidize substrates that contain complicated disulfide patterns. To explore alternate avenues of correct disulfide bond formation, we knocked out the DsbC gene and selected for suppressors that were able to efficiently form nonconsecutive disulfide bonds. The majority of the suppressors we obtained (Fig. 8B, class I) greatly overproduce DsbA and result in a shift towards more reduced DsbA. This enhances the ability of DsbA to facilitate the correct oxidation of proteins, but the copper sensitivity of these suppressors implies that they lack error-fixing ability. We did obtain a suppressor that apparently possesses error-fixing isomerase activity (Fig. 8C, class II suppressor). This suppressor (UVC56) also overproduces DsbA, although to a lesser extent, but in addition, overproduces the chaperone/protease DegP, which apparently enhances the ability of the strain to perform disulfide isomerization reactions.

Eukaryotic proteins often contain complicated disulfide connectivities. For example, tissue plasminogen activator containing 17 disulfides, potentially could have over 500 trillion disulfide isoforms. This puts extreme demands on cells to accomplish correct disulfide oxidation. Very high levels of DsbA are present in our class I DsbC suppressors, and very high levels of PDI are present in the endoplasmic reticulum of eukaryotes (42). These observations
raise the intriguing possibility that PDI may be acting to assist in vivo disulfide formation via a mechanism similar to what we postulate for the DsbA overproducers. That our DsbC suppressors worked in part by shifting the ratio of oxidized to reduced DsbA points out how critical it is to maintain the appropriate thiol disulfide redox balance for enabling proper disulfide bond formation in proteins with multiple cysteines. The emerging role of a redox driven feedback loop in determining the activity of Ero1 (1-2,35-36,40), the oxidase of PDI, suggests that the redox balance in the endoplasmic reticulum is strictly regulated as well. Elevation of the chaperone/protease DegP in our class II suppressor implies that chaperone activity also plays an important role in disulfide bond isomerization, which is consistent with the previous finding that both PDI and DsbC have chaperone activity (7,32,44). DegP may be able to help fold substrate proteins by bringing non-consecutive cysteines together in space followed by DsbA functioning as an oxidase. Our ability to select for correct disulfide bond formation in vivo opens up new strategies that may contribute to selecting bacteria with an enhanced capacity to express multi-disulfide containing proteins of pharmaceutical importance.
Acknowledgments

We thank Ursula Jakob and David Ballou for useful suggestions and for critically reading the manuscript. We thank David Akey for helping to generate figure 1A. We thank for Thomas Silhavy for providing antibody for DegP, and CpxP, and we thank for Rajeev Misra for providing antibody against OmpC, OmpA, and OmpF. J.C.A.B. is a Howard Hughes Medical Institute Investigator.

Author Disclosure Statement

No competing financial interests exist.
References


### Tables

#### Table 1. Strains and plasmids used in this study

<table>
<thead>
<tr>
<th>Strain name</th>
<th>Genotype/insert</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>ER1821 (wild type)</td>
<td>F' glnV44 e14 (McrA) rfbD1? relA1? endA1</td>
<td>New England Biolabs</td>
</tr>
<tr>
<td>RGP209</td>
<td>ER1821 dsbC</td>
<td>Lab stock</td>
</tr>
<tr>
<td>RGP433</td>
<td>ER1821 dsbC' dsbB</td>
<td>Lab stock</td>
</tr>
<tr>
<td>RGP663</td>
<td>ER1821+ pPDI detector</td>
<td>This study</td>
</tr>
<tr>
<td>RGP664</td>
<td>ER1821 dsbA' + pPDI detector</td>
<td>This study</td>
</tr>
<tr>
<td>RGP665</td>
<td>RGP209+ pPDI detector (the starting strain)</td>
<td>This study</td>
</tr>
<tr>
<td>RGP666</td>
<td>ER1821 dsbD' + pPDI detector</td>
<td>This study</td>
</tr>
<tr>
<td>RGP667</td>
<td>ER1821 dsbA' dsbC' + pPDI detector</td>
<td>This study</td>
</tr>
<tr>
<td>RGP668</td>
<td>ER1821 trxA' + pPDI detector</td>
<td>This study</td>
</tr>
<tr>
<td>RGP669</td>
<td>ER1821 trxB' + pPDI detector</td>
<td>This study</td>
</tr>
<tr>
<td>RGP181</td>
<td>ER1821+pBR322</td>
<td>This study</td>
</tr>
<tr>
<td>RGP188</td>
<td>ER1821 dsbA'+pBR322</td>
<td>This study</td>
</tr>
<tr>
<td>RGP195</td>
<td>ER1821 dsbC'+pBR322</td>
<td>This study</td>
</tr>
<tr>
<td>RGP286</td>
<td>ER1821 dsbD'+pBR322</td>
<td>This study</td>
</tr>
<tr>
<td>RGP202</td>
<td>ER1821 dsbA' dsbC'+pBR322</td>
<td>This study</td>
</tr>
<tr>
<td>RGP655</td>
<td>ER1821+ pBla 81-108</td>
<td>This study</td>
</tr>
<tr>
<td>RGP685</td>
<td>ER1821+ pBla 52-81</td>
<td>This study</td>
</tr>
<tr>
<td>RGP686</td>
<td>ER1821+ pBla 98-108</td>
<td>This study</td>
</tr>
<tr>
<td>RGP719</td>
<td>ER1821+ pBla 52-108</td>
<td>This study</td>
</tr>
<tr>
<td>RGP720</td>
<td>ER1821+ pBla 81-98</td>
<td>This study</td>
</tr>
<tr>
<td>RGP829→834</td>
<td>UVC49→54, dsbC' suppressor strains</td>
<td>This study</td>
</tr>
<tr>
<td>RGP843→848</td>
<td>UVC56→61, dsbC' suppressor strains</td>
<td>This study</td>
</tr>
<tr>
<td>RGP852</td>
<td>UVC62, dsbC' suppressor strains</td>
<td>This study</td>
</tr>
<tr>
<td>RGP877→880</td>
<td>UVC63→66, dsbC' suppressor strains</td>
<td>This study</td>
</tr>
<tr>
<td>RGP849</td>
<td>UVC49 cured the pBR322 plasmid</td>
<td>This study</td>
</tr>
<tr>
<td>RGP851</td>
<td>UVC52 cured the pBR322 plasmid</td>
<td>This study</td>
</tr>
<tr>
<td>RGP1079</td>
<td>ER1821 dsbB1-148 dsbC'</td>
<td>This study</td>
</tr>
</tbody>
</table>
  
  \((dsbB \text{ was truncated as in UVC56})\)

| RGP1126 | ER1821 dsbB1-148 dsbC' cpxRM231,E24K | This study |
  
  \((kdgT::kan)\)
<table>
<thead>
<tr>
<th>Plasmid name</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>pBR322</td>
<td>With wild type β-lactamase (Bla) in the vector Lab stock</td>
</tr>
<tr>
<td>pPDI detector</td>
<td>pBR322, Bla with mutations of S81C (TCA to TGT) and T108C (ACT to TGT) This study</td>
</tr>
<tr>
<td>pBla 81-108</td>
<td>pBR322 with Bla C52S C98S S81C T108C This study</td>
</tr>
<tr>
<td>pBla 52-81</td>
<td>pBR322 with Bla C98S S81C This study</td>
</tr>
<tr>
<td>pBla 98-108</td>
<td>pBR322 with Bla C52S T108C This study</td>
</tr>
<tr>
<td>pBla 81-98</td>
<td>pBR322 with Bla C52S S81C This study</td>
</tr>
<tr>
<td>pRDB8-a</td>
<td>Urokinase constitutively active in the periplasm Lab stock</td>
</tr>
<tr>
<td>pMPB</td>
<td>MBP and BPTI fusion protein in the periplasm This study</td>
</tr>
<tr>
<td>pETDsbsA</td>
<td>Codon optimized DsbA sequence Lab stock</td>
</tr>
<tr>
<td>pBADsbsA</td>
<td>DsbA expression induced by arabinose This study</td>
</tr>
</tbody>
</table>
Table 2. Ampicillin sensitivity of the yihG::kan P1 transduced suppressor strains

<table>
<thead>
<tr>
<th>Amp</th>
<th>*W</th>
<th>dsb</th>
<th>4</th>
<th>5</th>
<th>5</th>
<th>5</th>
<th>5</th>
<th>5</th>
<th>5</th>
<th>5</th>
<th>5</th>
<th>6</th>
<th>6</th>
<th>6</th>
<th>6</th>
<th>6</th>
<th>6</th>
<th>6</th>
</tr>
</thead>
<tbody>
<tr>
<td>(g/L)</td>
<td>T</td>
<td>C</td>
<td>9</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>6</td>
<td>7</td>
<td>8</td>
<td>9</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>0.2</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>3</td>
<td>6</td>
<td>4</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>1.5</td>
<td>6</td>
<td>6</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>6</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

*Amp, ampicillin.

Growth on plates containing 0.2 g/L ampicillin was used to indicate the presence of the PDI detector plasmid. Growth of the same strains on plates containing 1.5 g/L ampicillin was used to indicate isomerase activity. The values in the 0.2 g/L ampicillin row indicate the tested colonies and those in the 1.5 g/L row indicate the survivors. Only the wild type and UVC56 strains remained resistant to 1.5 g/L ampicillin after the dsbA region was substituted with wild type DNA by yihG::kan co-transduction using P1 phage (100% linkage).
Figure legends

**Fig. 1.** Design and characteristics of a PDI detector β-lactamase construct that links correct disulfide bond formation to bacterial antibiotic resistance. (A) Model structure of the TEM-1 β-lactamase PDI detector construct containing an engineered disulfide generated by cysteine substitutions at both serine 81 and threonine 108; model is based on the wild type crystal structure (1BTL). (B) Possible patterns of disulfide bond linkage within the PDI detector β-lactamase. The native disulfide bond in β-lactamase is C52-C98. A native-like disulfide (C81-C108) was engineered so as not to substantially disrupt the native structure. The native-like pattern (iii) is active (circled in green), whereas formation of other disulfides (ii and iv) inactivates β-lactamase (Fig. 2). Fully reduced PDI detector β-lactamase (i) is also expected to be active. (C) PDI detector β-lactamase exhibits decreased antibiotic resistance in *E. coli* mutants that are deficient in disulfide isomerization. Mutants lacking any known component of the disulfide isomerization pathway, namely, thioredoxin reductase (*trxB*), thioredoxin (*trxA*), DsbD (*dsbD*), or DsbC (*dsbC*), decrease the ampicillin resistance of strains containing the PDI detector. As expected from the full activity of reduced β-lactamase, strains containing the *dsbA*- mutation including *dsbA*− and *dsbA*− *dsbC*− are ampicillin resistant. (Spot titrations were performed on LB plates containing 1 g/L ampicillin (Amp) for various strains transformed with the PDI detector construct: pBR322 in RGP663 (wild type), RGP664 (*dsbA*−), RGP665 (*dsbC*−), RGP666 (*dsbD*−), RGP667 (*dsbA*− *dsbC*−), RGP668 (*trxA*−), and RGP668 (*trxB*−). (D) Analysis of the in vivo oxidation status of PDI detector β-lactamase by AMS trapping. The PDI detector is oxidized in the wild type strain, reduced in *dsbA*− and *dsbA*− *dsbC*− strains, and oxidized in...
dsbC\(^{-}\), dsbD\(^{-}\), trxA\(^{-}\), and trxB\(^{-}\) strains. (E) Addition of 1 mM of the reductant DTT restores the growth of PDI detector β’lactamase in dsbC\(^{-}\) and dsbD\(^{-}\) strains on media containing 1 g/L ampicillin.

**Fig. 2.** The C52-C98 or C81-C108 disulfides are the only ones that allow β-lactamase to retain activity. (A) In vivo activity of one disulfide bond containing β-lactamase mutants. The Western blot at the far left shows the expression level of each variant as measured from whole cells using β-lactamase antibody. The schemes in the middle indicate the names and linkages of the one disulfide bonded β-lactamase variants (engineered cysteines are shown in red; wild type cysteines are shown in black). The spot titer panel at the right shows their ampicillin (0.2 g/L) resistance. The single disulfide bonded variants showed decreased ampicillin resistance compared to wild type β-lactamase.

(B) A wild type strain containing wild type β-lactamase (52-98) (RGP181) grew well in liquid media containing 0.2 g/L ampicillin in the presence or absence of DTT (upper graph), whereas β-lactamase (C81-C108) (RGP655) grew somewhat in 0.2 g/L ampicillin, but only in the absence of DTT (lower graph). (C) 1 mM DTT restores the ability of wild type *E. coli* strains containing β-lactamase C52-C81 (RGP685) or β-lactamase C98-C108 (RGP686) to grow on media containing 0.2 g/L ampicillin. (D) 1 mM DTT also restores the ability of wild type strains containing β-lactamase C52-C108 (RGP719) or β-lactamase C81-C98 (RGP720) to grow in media containing 0.2 g/L ampicillin. The requirement of disulfide bond catalysis machinery for β-lactamase activity. (E) Cell-titer curves for strains expressing PDI detector β-lactamase based on the spot titer assay on ampicillin gradient plates. Shown are wild type
(RGP663), $dsbA^{-}$ (RGP664), $dsbC^{-}$ (RGP665), $dsbD^{-}$ (RGP666), $dsbA^{-}dsbC^{-}$ (RGP667), and $trxA^{-}$ (RGP668). The insert shows the thiol status of the PDI detector as revealed by in vivo AMS trapping ($F$) Cell-titer curves for strains expressing wild type $\beta$-lactamase based on the spot titer assay on ampicillin gradient plates. Shown are wild type (RGP181), $dsbA^{-}$ (RGP188), $dsbC^{-}$ (RGP195), $dsbD^{-}$ (RGP286), and $dsbA^{-}dsbC^{-}$ (RGP202).

**Fig. 3.** Schematic illustrating the genetic selection of $dsbC^{-}$ strain suppressors using the PDI detector. Ampicillin resistant derivatives of the $dsbC^{-}$ strain that contained the PDI detector $\beta$-lactamase plasmid were obtained following UV mutagenesis and plating on LB plates containing 1.5 g/L ampicillin (right panel). No colonies exhibiting this level of ampicillin resistance could be obtained by directly plating the starting strain without mutagenesis (left panel). Ampicillin resistant mutants obtained following mutagenesis (right panel) were then screened for cadmium sensitivity in order to eliminate mutants deficient in disulfide oxidation. Cadmium exerts its toxic effect by binding tightly to free thiols. Strains deficient in disulfide oxidation due to mutants in $dsbA$ or $dsbB$ have a high number of free thiols and are therefore cadmium sensitive (39) This provides an easy way to screen out $dsbA$ or $dsbB$ inactive mutants (approximately 95% of the ampicillin resistant colonies were eliminated in this secondary screening step). Mutants that were both ampicillin and cadmium resistant were streaked out for single colonies on plates containing 1.5 g/L ampicillin. Plasmids from the candidate strains (named UVC49-UVC66) were sequenced to verify that no mutation had occurred within the PDI detector construct. PCR was then used to verify that the strain still contained the original $dsbC$ deletion (UVC55 was excluded as it did contain the $dsbC$ gene).
**Fig. 4.** Mutations that suppress the $dsbC^-$ phenotype restore the ability to form disulfides correctly and greatly overexpress DsbA. (A) Restored ampicillin resistance of $dsbC^-$ suppressor strains. Spot titrations were performed on LB plates containing various concentrations of ampicillin (Amp) using the following strains: wild type (RGP663), $dsbC^-$ (RGP665), UVC49 (RGP829), UVC52 (RGP833), UVC56 (RGP843), and UVC61 (RGP848). (B) Restoration of mouse urokinase activity in three $dsbC^-$ suppressor strains (UVC49, UVC52, and UVC56). Urokinase activity was detected by a casein agar assay as described in SI Materials and Methods. Dark blue bands indicate activity. (C) DsbA is highly overexpressed in the $dsbC^-$ suppressors. An equal quantity of bacterial cells of the various $dsbC$ suppressors was resolved on a reducing SDS gel and the blot was probed with a DsbA antibody. The number under the bands indicates the suppressor’s UVC number (e.g., 49 is UVC49), the $dsbC^-$ cells used in the first lane were from the starting, unmutagenized strain, RGP665. (D) Detection of DsbA and DsbA-substrate complexes in vivo in wild type bacteria, $dsbC^-$ strain, and in UVC49, UVC52, and UVC56 by Western analysis. Equal amounts of cells (left panels) were AMS-acid trapped and loaded to nonreducing (upper panel) and reducing gels (lower panel). This allowed detection of the amount of DsbA present on a per cell basis. To get an idea of the relative amount of oxidized and reduced DsbA and DsbA-substrate complexes on a per DsbA basis, dilutions of each cell sample were made such that approximately equal quantities of DsbA protein were loaded (right panels). The UVC49 and UVC52 samples were thus diluted 50-fold and the UVC56 sample was diluted 5-fold before loading; all other samples were not diluted as indicated by a “-”. The blots were probed with DsbA antibody. (E) Various pathways of
substrate protein (abbreviated as P) oxidation by the DsbA protein. Disulfides are shown as S-S, free thiols as SH. Red indicates oxidized, blue reduced.

**Fig. 5.** DsbA overexpression is necessary and sufficient for the ability of the suppressor strains to express proteins with complex disulfide bond patterns. (A) DsbA is massively overexpressed in the suppressor strains as measured by Western blot (~50-fold in most of the DsbC suppressors and ~5-fold in UCV56). Samples for suppressor strains were diluted 50-fold prior to loading except for UVC56, which was diluted 5-fold. (B) Spot titer for strains expressing the PDI detector on LB plates and on those containing 0.6 g/L ampicillin. The *dsbA* gene from UVC49 was moved into the *dsbC* strain (RGP1269) by P1 co-transduction using the closely linked marker *yigZ::kan*. Strain genotypes are indicated at the far left: wild type (RGP663), *dsbC* (RGP665), UVC49 (RGP829), and *dsbC* *yigZ::kan* (RGP1269). DsbA expression level as determined by Western blot of whole cell extracts using antibody against DsbA is shown at the right. (C) Restoration of BPTI activity provides an independent indication that the correct disulfide bond formation capacity is restored in these suppressors. BPTI amount was quantified by a trypsin activity inhibition assay. Strains shown are wild type (RGP860), *dsbC* (RGP862), UVC49 (RGP856), UVC52 (RGP858), and UVC56 (RGP1130). (D) To obtain more evidence that DsbA overexpression in the class I DsbC suppressors is by itself sufficient to rescue the DsbC null phenotypes, we transformed the DsbC null strain with a plasmid that had DsbA expression under the inducible arabinose BAD promoter. Induction of DsbA expression to levels comparable to those present in the class I suppressor UVC52 (by adding arabinose to the media) restored urokinase activity to wild type levels, confirming that
high levels of DsbA overexpression are sufficient to complement $dsbC$. Urokinase activity was detected by a casein agar assay as shown on the upper lane. DsbA expression level was detected by Western blot as shown on the lower lane. Strains shown are wild type (RGP1181), $dsbC^-$ (RGP1182), UVC49 (RGP1183), UVC52 (RGP1184), UVC56 (RGP1185), and $dsbC^- pBADDsbA$ (RGP1244). The triangle indicates increasing amounts of arabinose added to the media at 0%, 0.0015%, 0.015%, 0.15%, and 1.5%. (E) Copper resistance of $dsbC^-$ suppressors. UVC56 is more copper resistant than wild type strains; all other DsbC suppressors were copper sensitive, with most no more copper resistant than the $dsbC^-$ strain and some even more copper sensitive. Strains used from left to right were RGP663, RGP665, RGP829–834, RGP843–848, RGP852, RGP877–880.

**Fig. 6.** Mutated $cpxR$ directs DsbA to proofread misoxidized disulfides with the assistance of the chaperone DegP. (A) Ampicillin resistance of UVC56, UVC56 $cpxR^+$, UVC56 $dsbB^+$, UVC56 $cpxR^+ dsbB^+$, and RGP1146 strains; wild type, $dsbC^-$, and $dsbB^- dsbC^-$ strains were used as controls. (B) Analysis of the in vivo oxidation status of DsbA by AMS trapping in UVC56 and wild type strains (C) Western blot showing up-regulation of DegP in UVC56. (D) Copper resistance of UVC56, RGP1146, UVC56 $cpxR^+$ (RGP1071), UVC56 $dsbA^-$ (RGP916), and UCV56 $degP^-$ (RGP1256); wild type and $dsbC^-$ strains were used as controls. Experiments were done at both 37 degrees where the protease activity of DegP is upregulated and at 29 degrees where DegP’s chaperone activity should dominate(45).
Fig. 7. Characterization of the class II DsbC suppressor UVC56. (A) Cystine or GSSG in the minimal media fully restores UVC56 motility independent of \( dsbB \) but dependent on \( dsbA \). Motility assays were performed in minimal media (top) or supplemented with 0.83 mM cystine (bottom left) or 0.83 mM GSSG (bottom right). The strain genotypes are: 1, the starting strain \( dsbC^- \) (RGP663); 2, UVC56 (RGP843); 3, UVC56 \( dsbA^- \) (RGP916); 4, UVC56 \( dsbB^- \) (RGP917); 5, UVC56 \( dsbD^- \) (RGP918); 6, UVC56 \( dsbG^- \) (RGP919); and 7, \( dsbC^-dsbB^- \) (RGP433). (B) Cadmium resistance of UVC56, UVC56 \( cpxR^+ \) (RGP1073), and \( dsbB^-dsbC^-cpxR56 \) (RGP1126); wild type, \( dsbC^- \), and \( dsbB^-dsbC^- \) strains were used as the controls. Cell titer curves were generated from the gradient spot titer data. (C) 5-fold overexpression of DsbA from plasmid can rescue the cadmium resistance of \( dsbB^-dsbC^- \) (RGP1249), but fails to rescue copper resistance. These results suggest that the isomerase activity gained by UVC56 requires more than 5-fold DsbA overexpression. DsbA expression was induced by adding arabinose to the media at the concentrations shown and was confirmed by Western blot of whole cell extracts using antibody against DsbA (bottom panel).

Fig. 8. Potential strategies for forming correct disulfide connectivity patterns in vivo. (A) DsbC-dependent proofreading of substrates with mismatched disulfides. DsbA forms consecutive disulfide bonds co-translocationally. For substrates that require nonconsecutive disulfides, DsbC either reshuffles them or reduces them followed by another round of DsbA-mediated oxidation. (B) We postulate that the class I suppressor strategy involves DsbA-dependent error-less oxidation of substrates. A high level of DsbA increases the level of DsbA-substrate complexes, which in turn increases the opportunity for correct folding. Correct
folding then directly favors correct disulfide bond formation, even in the case where the correct disulfides are nonconsecutive. A small amount of protein as indicated by the red dotted reaction is oxidized consecutively and incorrectly. (C) We postulate that the class II suppressor strategy involves chaperone-assisted DsbA correction of mismatched disulfides. DsbA co-translocationally oxidizes substrates, forming mixed disulfides with DsbA and preventing formation of incorrect disulfide bonds within the protein. After normal folding processes bring the proper cysteines into proximity, the proper disulfides of the protein are found as shown in Fig 4E. The proteins containing nonnative disulfides are later isomerized by DsbA with the assistance of DegP. The isomerase reactions diagramed in this figure involve a multistep process involving the attack of incorrect disulfides by reduced DsbC or reduced DsbA, which results in the formation of a mixed disulfide between these oxidoreductases and the substrate protein. This is followed by internal rearrangements of the disulfide bonding pattern. This multistep process is simplified in the diagrams by a single arrow labeled isomerization.
Engineered pathways for correct disulfide bond oxidation (doi: 10.1089/ars.2010.3782)

This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.